Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
about
Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.Inhibition of platelet activation could decrease thrombotic events in hemodialysis PF4/H antibody-positive patients.Genetic determinants of on-aspirin platelet reactivity: focus on the influence of PEAR1.Reduced-function CYP2C19 genotype and risk of adverse clinical outcomes among patients treated with clopidogrel predominantly for PCI: a meta-analysis.The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.Clinical, pharmacokinetic, and pharmacogenetic determinants of clopidogrel resistance in Korean patients with acute coronary syndrome.Protein kinase C regulation of 12-lipoxygenase-mediated human platelet activation.PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes.Cardiovascular pharmacogenomics: the future of cardiovascular therapeutics?Predicting clopidogrel response using DNA samples linked to an electronic health record.Review: Antiplatelet drugs: what comes next?Genetic determinants of on-clopidogrel high platelet reactivity.Antiplatelet drug therapy: role of pharmacodynamic and genetic testing.Genetic determinants of platelet response to clopidogrel.The pharmacogenetics of antiplatelet agents: towards personalized therapy?TRITON and beyond: new insights into the profile of prasugrel.Importance of potent P2Y(12) receptor blockade in acute myocardial infarction: focus on prasugrel.Role of genotype-based personalized antiplatelet therapy in the era of potent P2Y₁₂ receptor inhibitors.Management of Coronary Artery Disease in South Asian Populations: Why and How to Prevent and Treat Differently.Feasibility of clinical pharmacist-led CYP2C19 genotyping for patients receiving non-emergent cardiac catheterization in an integrated health system.Meta-analysis of effects of ABCB1 polymorphisms on clopidogrel response among patients with coronary artery disease.Characterization of drug-metabolizing enzymes CYP2C9, CYP2C19 polymorphisms in Tunisian, Kuwaiti and Bahraini populations.Clopidogrel: a pharmacogenomic perspective on its use in coronary artery disease.Responding to the clopidogrel warning by the US food and drug administration: real life is complicated.Platelet aggregation pathway.Impaired responsiveness to clopidogrel and aspirin in patients with recurrent stent thrombosis following percutaneous intervention for peripheral artery disease.CYP2C19 genotypes and their impact on clopidogrel responsiveness in percutaneous coronary intervention.Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease.CYP2C19 and PON1 polymorphisms regulating clopidogrel bioactivation in Chinese, Malay and Indian subjects.Identifying clinically relevant sources of variability: The clopidogrel challenge.Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study
P2860
Q33365061-F7A129F8-9093-4122-B145-14D4631997AFQ33414182-1F9C3413-6AC1-46C5-A1AC-0A127FCF3600Q34435298-754990CD-2785-4E4C-A94B-ACC921A54EB1Q34624862-EA6503BC-969E-446A-90C9-E7C229CBE1A7Q34703779-BD27C220-9CB4-4429-AFB9-4C52DC7B076AQ35048059-7E7D2D3A-C3BE-49F6-9840-644CDD7578F4Q35776733-E1453EB4-CB24-4023-ADBB-62DA1B556474Q35952367-33C656AC-9F3A-48E0-8563-DF04C6EE6E1EQ36094919-15CF6E6B-D45B-4E57-8F82-51559E9774F0Q36487290-8AD3D779-6864-47C4-B2BE-82BD9C714A3FQ36753929-5371C995-9F18-4384-B309-92C9F856CC0AQ37809630-580BE4FA-CE24-492D-85D6-A440D1A08780Q37882695-EC657C71-07A2-4A28-9BA7-7FA0AD9A53A0Q37882712-97B88C00-650B-4F42-8849-C982F7FACD93Q37894590-06CD40CC-59CE-4F19-9F0B-F0E993910E7DQ37913976-9D6CCCAA-F53A-44AB-B7E2-459F732ABF64Q37925009-8DA61553-8577-4B61-B32C-F0EF88B9C4AAQ38025446-2C68CA94-9ECF-47AC-B294-7D02B2C3591AQ38048837-14AF0D05-1597-441E-A3B6-CDCF31E70AA7Q38476938-D625AE88-ADA4-41C3-83E4-53A74D4DD4B5Q38660595-F48F988E-85F6-47E7-ABE8-AEA956848031Q38734885-DEA5434D-60A8-49C9-8005-E2A79D13094BQ38855703-ACB386E0-E895-4AFA-B367-B35F934A52E5Q41141258-F996B644-6FA6-4714-B76E-0E7FB449BAF1Q42533914-D61D0D18-1D66-451F-8C21-DA2071D188C4Q42796609-31A6C456-CF01-4A81-8441-C7BDFE38CD5FQ44085111-0598B131-B3B6-45B8-BDE6-CAE644587D50Q44906555-CE90C07F-BCDD-4400-8FAA-2D874E2B799FQ44986245-D1C90241-3C02-4B6B-B6C4-E9FBC22C2BA7Q47961774-F572B3F9-CAA5-4730-9673-948E3A5CDA24Q50591900-C97C4959-D26D-4577-8EB6-D30FCD6767B1Q58071120-05746827-9B38-4C85-8A0A-06BFA2974DC6
P2860
Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
description
2010 nî lūn-bûn
@nan
2010 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
@ast
Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
@en
type
label
Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
@ast
Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
@en
prefLabel
Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
@ast
Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
@en
P2093
P1476
Genotyping: one piece of the puzzle to personalize antiplatelet therapy.
@en
P2093
Dean J Kereiakes
Paul A Gurbel
Udaya S Tantry
P304
P356
10.1016/J.JACC.2010.04.008
P407
P577
2010-05-13T00:00:00Z